Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial

Jonathan A. Ledermann, Andrew Embleton, Fharat Raja, Timothy J. Perren, Gordon C. Jayson, Gordon J. S. Rustin, Stan B. Kaye, Hal Hirte, Elizabeth Eisenhauer, Michelle Vaughan, Michael Friedlander, Antonio Gonzalez-Martin, Daniel Stark, Elizabeth Clark, Laura Farrelly, Ann Marie Swart, Adrian D. Cook, Richard S. Kaplan, Mahesh K. B. Parmar

Norwich Medical School
Norwich Clinical Trials Unit
Cardiovascular and Metabolic Health
Health Services and Primary Care
Public Health and Health Services Research

Research output: Contribution to journal › Article › peer-review

167 Citations (SciVal)

5 Downloads (Pure)

1 results
- Last Name(ascending)

Ann Marie Swart
- A.Swart@uea.ac.uk
- Norwich Medical School - Professor of Medicine (Epidemiology)
- Cardiovascular and Metabolic Health - Member
- Health Services and Primary Care - Member
- Norwich Clinical Trials Unit - Member
- Public Health and Health Services Research - Member
Person: Research Group Member, Academic, Teaching & Research

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial

Profiles

Search results

Ann Marie Swart